Somatic mutations in BRAF occur in ~3–8% of adenocarcinoma cases; of these, ~50% are BRAF V600E, which is predictive for vemurafenib and dabrafenib-based therapies [5]. This evidence concerns the gene BRAF and adenocarcinoma.